Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan

Detalles Bibliográficos
Autores principales: Yanagi, Yasuo, Takahashi, Kanji, Iida, Tomohiro, Gomi, Fumi, Morii, Junko, Kunikane, Eriko, Sakamoto, Taiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442042/
https://www.ncbi.nlm.nih.gov/pubmed/37566304
http://dx.doi.org/10.1007/s40123-023-00788-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442042/
https://www.ncbi.nlm.nih.gov/pubmed/37566304
http://dx.doi.org/10.1007/s40123-023-00788-9

Ejemplares similares